GlassScriptPhysician profile
Leia Sullivan
NPI 1104679240
$2,483.27
in general payments reported to CMS, 2019-2025
22 companies · $1,619 in 2025
The $1,619 reported for 2025 was more than what 90% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $865 · 2025: $1,619.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,384 · Education: $99.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,384.27 |
| Education | $99.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $929.62 | 2024-2025 | |
| Janssen Biotech, INC. | $324.70 | 2025 | Tremfya |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $197.44 | 2024-2025 | Xifaxan, Trulance |
| Phathom Pharmaceuticals, INC. | $147.60 | 2024-2025 | Voquezna |
| Janssen Scientific Affairs, LLC | $145.98 | 2024 | Tremfya, Stelara |
| Madrigal Pharmaceuticals | $96.24 | 2024-2025 | Rezdiffra, Resmetirom |
| Genzyme Corporation | $81.43 | 2024-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $78.00 | 2025 | Entyvio |
| Aimmune Therapeutics, INC. | $75.66 | 2025 | Zenpep |
| Ardelyx, INC. | $66.02 | 2025 | Ibsrela |
| Novo Nordisk INC | $60.86 | 2025 | Wegovy |
| Intercept Pharmaceuticals, INC. | $45.39 | 2024-2025 | |
| Vivus LLC | $45.22 | 2024 | Pancreaze |
| Pfizer INC. | $37.19 | 2024-2025 | |
| Fresenius Kabi USA, LLC | $24.46 | 2024 | Idacio |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Celltrion USA INC. | $21.20 | 2024 | Vegzelma |
| Lilly USA, LLC | $19.23 | 2024 | Omvoh |
| Gilead Sciences, INC. | $18.96 | 2024 | |
| Braintree Laboratories, INC. | $18.38 | 2024 | Sutab, Suflave |
| E.R. Squibb & Sons, L.L.C. | $18.21 | 2024 | Zeposia |
| Teva Pharmaceuticals USA, INC. | $16.40 | 2024 | Simlandi |
| Ferring Pharmaceuticals INC. | $15.08 | 2024 | Rebyota |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Leia Sullivan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.